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Abstract
Background: Biofilms contribute to the pathogenesis of many forms of Staphylococcus aureus infection. Treatment of these
infections is complicated by intrinsic resistance to conventional antibiotics, thus creating an urgent need for strategies that
can be used for the prevention and treatment of biofilm-associated infections.
Methodology/Principal Findings: This study demonstrates that a botanical natural product composition (220D-F2) rich in
ellagic acid and its derivatives can limit S. aureus biofilm formation to a degree that can be correlated with increased
antibiotic susceptibility. The source of this composition is Rubus ulmifolius Schott. (Rosaceae), a plant used in
complementary and alternative medicine in southern Italy for the treatment of skin and soft tissue infections. All S.
aureus clonal lineages tested exhibited a reduced capacity to form a biofilm at 220D-F2 concentrations ranging from 50–
200 mg/mL, which were well below the concentrations required to limit bacterial growth (530–1040 mg/mL). This limitation
was therapeutically relevant in that inclusion of 220D-F2 resulted in enhanced susceptibility to the functionally-distinct
antibiotics daptomycin, clindamycin and oxacillin. Testing with kidney and liver cell lines also demonstrated a lack of host
cell cytotoxicity at concentrations of 220D-F2 required to achieve these effects.
Conclusions/Significance: These results demonstrate that extract 220D-F2 from the root of Rubus ulmifolius can be used to
inhibit S. aureus biofilm formation to a degree that can be correlated with increased antibiotic susceptibility without toxic
effects on normal mammalian cells. Hence, 220D-F2 is a strong candidate for development as a botanical drug for use in the
prevention and treatment of S. aureus biofilm-associated infections.
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Introduction
Staphylococcus aureus is arguably the most problematic of all
bacterial pathogens owing in large part to the persistent
emergence of antibiotic resistant strains. This is evident in the
recent appearance of methicillin-resistant strains even among
isolates causing community-acquired infections [1,2,3]. While this
has created an urgent need for new antimicrobial agents, many S.
aureus infections are recalcitrant to antimicrobials even in the
absence of issues related to acquired-antibiotic resistance. A
primary contributing factor to this recalcitrance is the formation of
a biofilm. Indeed, the National Institutes of Health estimates that
80% of all bacterial infections are biofilm related [4]. In addition
to their impact on antimicrobial therapy, bacteria within biofilms
reach a much higher density (10
11 CFU/mL) than their plank-
tonic counterparts (10
8 CFU/mL) [5], thus increasing the opportu-
nity for gene transfer and the emergence of strains with new resistance
a n d / o rv i r u l e n c ep r o f i l e s .T h ep r e s e n c eo faf o r e i g nb o d yd e c r e a s e st h e
minimal infecting dose of S. aureus .100,000-fold [6], thus significantly
increasing the chances of a biofilm-associated infection by comparison
to individuals without such devices. In most cases, treatment of such
biofilm-associated infections requires both aggressive antimicrobial
treatment and surgical debridement to remove all infected tissues and/
or indwelling medical devices [7,8].
The paradigm of biofilm resistance presents a major hurdle for
the treatment of many types of infectious disease, including dental
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osteomyelitis [5]. The economic burden of these infections is
tremendous with biofilm-associated infections lead to longer
hospital stays, recurrent infection, and increased fatalities in the
most recalcitrant cases. In total, up to 17 million new biofilm
infections occur each year in the US, resulting in up to 550,000
fatalities annually [9,10]. These statistics emphasize the fact that,
while there is indeed a pressing need for new antibiotics, there is
an equally urgent need to develop agents that could be used to
limit biofilm formation to a therapeutically relevant degree. Such
agents could be used to prevent colonization or as adjunct therapy
to enhance the therapeutic efficacy of conventional antibiotics
[10,11].
Taking an ethnobotanical approach to drug discovery [12] offers
considerable promise in many clinical contexts including infectious
disease.Indeed,studiesonbotanicalcomplementaryandalternative
(CAM) therapies have led to the discovery of novel ant-virulence
agents. For instance, proanthocyanidins from Vaccinium macrocarpon
(cranberry) disrupt adhesion of P-fimbriated E. coli to uroepithelial
cells [13,14], accounting for efficacy in preventing recurrent urinary
tract infections [15]. Garlic extract (Allium sativum) attenuates
virulence by inhibiting hyphae formation in Candida albicans [16]
andbyblocking quorumsensing inPseudomonas aeruginosa [17,18,19].
In S. aureus, inhibitors of quorum sensing, biofilm formation, and the
NorA efflux pump have all been isolated from botanical sources
[20,21,22,23,24,25,26,27,28,29]. Natural products offer a distinct
advantage over their synthetic counterparts due to their rich
structural diversity, chirality, and extensive functional group
chemistry [24]. Thus, plants are a likely source of the next
generation of anti-infectives [30].
Rubus ulmifolius Schott., Rosaceae (Elmleaf blackberry) is a wild
shrub native to the Mediterranean. A limited number of published
studies that have examined the antibacterial properties of R.
ulmifolius. For example, Flamini et al. [31] identified an anthrone
(Rubanthrone A) in the leaves, branches and flowering tops of R.
ulmifolius that had an MIC of 4,500 mg/mL against S. aureus
(ATCC 25923). Panizzi et al. [32] examined a crude extract of R.
ulmifolius leaves, flowering tops and branches as well as subsequent
extracts of increasing polarity for antibacterial activity using the
same S. aureus strain and found that the greatest activity was
present in the crude extract. The importance of R. ulmifolius as a
traditional medicine was highlighted in an ethnobotanical field
study conducted in rural communities of southern Italy [33]. In
particular, the fresh leaves are topically applied with pork fat in the
treatment of skin and soft tissue infections (SSTI) and a decoction
of the roots is used as a wash to prevent hair loss. In a screening
study that followed this fieldwork, ethanolic extracts from 104
Italian plants were assessed for their anti-biofilm potential and
extracts from R. ulmifolius and nine other species were found to
show some promise [28]. Here, we expanded on this work to
determine whether bioassay-guided fractionation could be used to
isolate a more potent extract of R. ulmifolius and whether this
extract could limit biofilm formation in genotypically and
phenotypically-diverse strains of S. aureus to a degree that can be
correlated with increased antibiotic susceptibility.
Results
Bioassay-guided fractionation of the active constituents
Fractionation of the crude ethanolic root extract was done as
illustrated in Fig. 1. The activity of each fraction was assessed
based on the ability to limit biofilm formation in a microtiter plate
assay using the methicillin-sensitive (MSSA) strain UAMS-1 and
the methicillin-resistant (MRSA) USA300 isolate FPR3757
(UAMS-1782). The greatest degree of inhibition was observed in
the butanol partition of the aqueous phase obtained after
successive extraction with hexane and ethyl acetate (Fig. 2).
Further partitioning of the butanol extract with MeOH:CH2Cl2
demonstrated that the greatest activity was observed with fractions
ranging from 40:60 to 60:40 MeOH:CH2Cl2 (220D-F2, 220D-F3
and 220D-F4). In fact, all three of these fractions limited biofilm
formation in this assay in a dose dependent manner and to a
degree that exceeded that observed with mutation of sarA (Fig. 2).
Moreover, biofilm assays confirmed that the activity in these
extracts was increased by comparison to the crude extract while
activity in other MeOH:CH2Cl2 extracts was decreased. This was
true with both UAMS-1 and UAMS-1782 although at the lowest
concentration tested (50 mg/mL) inhibition was slightly greater
with the former by comparison to the latter (Fig. 2). While
comparable inhibition was observed with the 220D-F2, 220D-F3
and 220D-F4 partitions, overall yield was greatest with 220D-F2
with a percent yield of 0.329% of dry root weight (3.29 g per kg of
dry root weight). For this reason, 220D-F2 was selected for
subsequent experiments.
A preparative reversed-phase high-performance liquid chroma-
tography (RP-HPLC) method was developed to further separate
220D-F2 into four fractions. Bioassays for biofilm inhibition with
these fractions revealed that no single fraction was more effective
than 220D-F2 itself, suggesting that more than one fraction was
necessary for the anti-biofilm activity (Fig. 3). Thus, additional
experiments were conducted in which fractions were combined in
all possible permutations and tested for activity (data not shown).
The only combination in which activity was restored was when all
four fractions were recombined (Fig. 3). These results were also
compared with 220D-F2 before and after running through the
HPLC system to determine if the separation protocol itself had any
effect on the activity. No significant difference between samples
could be determined. These data suggest that the anti-biofilm
effect of 220D-F2 is due to the synergistic activity of multiple
compounds, and that the relative proportions of this mixture is
important to the activity.
Identification of Active Constituents
LC-UV/MS/MS(liquid chromatography-ultraviolet absorption-
tandem mass spectrometry) studies on 220D-F2 revealed the
presence of ellagic acid (EA) and several ellagic acid derivatives
(EADs) or sapogenin-related compounds. Molecular formulas of
C14H6O8,C 20H16O12,C 19H14O12,C 30H46O7,C 30H46O8(Table1)
were identified and confirmed with accurate mass measurements
(,5 ppm). Possible structures for three of these components
(C14H6O8,C 20H16O12,C 19H14O12) are shown in Fig. 4. Neutral
loss of a pentose group (m/z 132) was observed for peaks 1 (m/z 435)
and 3 (m/z 449). A product ion of m/z 303 was observed for both of
these peaks suggesting that both components contain an ellagic acid
core. A similar product ion was not observed for peaks
corresponding to molecular formulae C30H46O7,a n dC 30H46O8
suggesting that thesecompoundsdo not containan ellagicacid core.
Likely structures of minor constituents in 220D-F2 could not be
determined from these studies.
Prophylactic efficacy of 220D-F2 in limiting S. aureus
biofilm formation
The ability of 220D-F2 to limit biofilm formation was assessed
against 15 genotypically-diverse clinical isolates of S. aureus. The
MBIC90 for these strains ranged from 50–200 mg/mL (Fig. 5). The
MIC and MBC was also determined for all 15 strains, with the
MIC90 ranging from 530–1040 mg/mL and the MBC90 from 530–
2040 mg/mL (Table 2). The observation that the MBIC90 was at
R. ulmifolius Extract Inhibits S. aureus Biofilms
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MBC90 indicates that the inhibition of biofilm formation observed
with 220D-F2 was due to something other than growth limitation.
This was confirmed by demonstrating that, while the presence of
the extract did delay entry into the exponential growth phase by
,2 hours, cultures with and without 220D-F2 reached the same
density within 12 hours and maintained the same cell counts
throughout the stationary growth phase (Fig. 6).
The ability of 220D-F2 to inhibit biofilm formation was also
confirmed by confocal microscopy (Fig. 7). At concentrations as
low as 50 mg/mL, the degree of inhibition observed with 220D-F2
was comparable to that associated with mutation of sarA in both
UAMS-1 and the USA300 isolate UAMS-1782 at concentrations
as low as 50 mg/mL. More specifically, the untreated wild-type
strains formed uniform biofilms with a thickness ranging from 88–
92 mm while the isogenic sarA mutants and parent strains exposed
to 220D-F2 formed very patchy biofilms with a few isolated
clumps of adherent cells.
Therapeutic efficacy of 220D-F2 in removal of established
S. aureus biofilms
The microtiter plate assay used in the experiments discussed
above does not lend itself easily to studies assessing relative
antibiotic susceptibility. To address this, we employed an in vitro
model of catheter-associated biofilm formation [34]. In order to
assess the impact of 220D-F2 relative to an isogenic sarA mutant,
we first examined the ability of 220D-F2 to inhibit colonization of
the catheters. The total number of viable cells adherent to
catheters following exposure to 220D-F2 during colonization was
significantly reduced by comparison to the untreated control
(P,0.05) and comparable to the number observed with the
isogenic sarA mutant. Although the actual reduction in the number
of adherent cells was relatively modest (1.23610
6 CFU/catheter
in the presence of 220D-F2 versus 1.34610
7 CFU/catheter in the
untreated control), previous work comparing UAMS-1 with its
isogenic sarA mutant demonstrated that a similar level of inhibition
was sufficient to improve the therapeutic response of a biofilm-
associated infection to antimicrobial therapy under both in vitro
and in vivo conditions [35].
Based on these results, we used the in vitro catheter model to
examine the therapeutic efficacy of 220D-F2 with and without
concomitant antimicrobial therapy. In the absence of antibiotic,
220D-F2 had no impact on an established biofilm even after 7
consecutive days of exposure (Fig. 8). However, exposure of a
UAMS-1 biofilm to 200 mg/mL 220D-F2 concomitantly with
different antibiotics (daptomycin, clindamycin, and oxacillin) was
Figure 1. Fractionation scheme for the separation of anti-biofilm constituents found in the roots of Rubus ulmifolius.
doi:10.1371/journal.pone.0028737.g001
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antibiotic alone. For example, catheters exposed to 220D-F2 and
10 mg/mL daptomycin (106 breakpoint MIC) exhibited average
colony counts of 3.37610
3 CFU/catheter while those exposed to
daptomycin alone exhibited colony counts of 1.01610
7 (Fig. 8).
Enhanced efficacy was also observed with clindamycin and
oxacillin. For example, exposure to 220D-F2 and clindamycin
(106) for 7 consecutive days resulted in a ,2.5 log reduction by
comparison to antibiotic alone (Fig. 8). Although we did not observe
a significant difference between oxacillin and oxacillin+220D-F2
when oxacillin was used at a 106concentration, when used at a
concentration corresponding to the MIC of UAMS-1 (0.5 mg/mL),
catheters exposed to 220D-F2 and oxacillin exhibited up to a 2–5
log reduction (depending on the number of days of exposure) by
comparison to oxacillin alone (Fig. 8).
An experiment in which 220D-F2 was added to the growth
medium during biofilm formation and then included with and
without daptomycin (106) during the treatment phase of the
experiment was also undertaken. Colony counts in the group
exposed to daptomcyin alone were reduced to 3.37610
6 CFU/
catheter on day 1 while those in the group exposed to both 220D-
F2 and daptomycin were reduced to 1.93610
3 CFU/catheter
(Fig. 9). This effect was even more apparent after 7 days of
exposure, with colony counts on catheters exposed to daptomycin
alone falling to 3.27610
4 CFU/catheter and those exposed to
daptomycin and 220D-F2 falling to 8.87610
1. Moreover, $33%
of all catheters exposed to both 220D-F2 and daptomycin were
cleared of all adherent cells (lower detection limit of 10 cells/
catheter) beginning on day 2 and continuing on all treatment days
thereafter.
Anti-biofilm activity of select R. ulmifolius constituents
Ten commercially available phytochemical constituents report-
ed in the literature [31,32,36] to have been isolated from R.
Figure 2. Biofilm inhibition of R. ulmifolius root extracts. A static microtiter plate biofilm assay which employed crystal violet as a biofilm matrix
staining agent was used to assess the inhibitory activity of individual fractions from the R. ulmifolius root using UAMS-1 (A) or the USA300 isolate
UAMS-1782 (B) as the wild-type (wt) test strains. Isogenic sarA mutants for each strains were included as controls. Other designations refer to the
specific extract as defined by the fractionation scheme illustrated in Figure 1. The MBICs for the crude EtoH extract (220), butanol partition (220D),
and 40:60 (220D-F2), 50:50 (220D-F3), and 60:40 (220D-F4) MeOH:CHCl2 fractions from the butanol partition were 200, 100, 50, 50 and 50 mg/mL,
respectively in both UAMS-1 and UAMS-1782. Statistical significance (*, P,0.05; {, P,0.001) refers to differences observed in each parent strain with
and without the indicated extract at the indicated concentration.
doi:10.1371/journal.pone.0028737.g002
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activity of fractions of 220D-F2 both alone and in combination using UAMS-1. No single fraction of 220D-F2 exhibited improved biofilm-inhibiting
activity over 220D-F2 as a whole. Multiple combinations of the fractions were made and the only combination which resulted in restoration of activity
on the same level as 220D-F2 was when all 4 fractions (f1+f2+f3+f4) were recombined. Likewise, a single collection, in which 220D-F2 was run through
the HPLC system and collected as a whole (instead of splitting into fractions) also resulted in the same level of activity as the original 220D-F2. These
findings suggest that multiple components found in extract 220D-F2 are necessary for the anti-biofilm activity. Statistical significance (*, P,0.05; {,
P,0.001) refers to differences observed in comparison to the untreated control.
doi:10.1371/journal.pone.0028737.g003
Table 1. Compounds detected in extract 220D-F2 by accurate mass LC/UV/MS/MS.
# Proposed Compound
{
Molecular
Formula
Retention Time
(minutes) [M+H]
+ m/z MS-MS Fragmentation (m/z)
1 Ellagic acid xylopyranoside or
Ellagic acid xylofuranoside
C19H14O12 10.9 435.05594 303.01346
2 Ellagic acid C14H6O8 11.1 303.01354 285.00281, 275.01868, 259.02338, 241.01314
3 Ellagic acid mannopyranoside C20H16O12 11.1 449.07158 352.33952, 303.01366, 249.11220, 182.98514
4 unknown unknown 11.5 437.97815 409.09189, 303.01351, 219.10153, 182.98507
5 Sapogenin derivative C30H46O8 13.5 535.32637 517.31604, 499.30499, 481.29480, 469.29486
6 Sapogenin derivative C30H46O7 13.7 519.33139 and
501.32097
501.32071, 483.31012, 473.32559, 455.31543,
437.30457, 409.30994
7 unknown unknown 14.7 573.98540 and
396.98622
532.95864, 505.35274, 485.32649, 451.99400,
440.95009, 352.33958, 317.02929, 273.07586,
199.98796, 182.98517
8 unknown unknown 16.9 1017.62898 and
999.61893
955.62813, 937.61896, 499.30520, 437.30489
{Proposed structures corresponding to this data are reported in Figure 4. Of the major UV components identified, the most abundant was EA (#2, MW 302). The second
most abundant UV component (#7) did not yield a clear MS signal suggestive of a single species or reasonable molecular formula, and thus no structure is proposed.
The third most abundant UV component (#1, MW 434) appears to be EA plus a C5H8O4 moiety. A fourth UV component (#3, MW 448) was found to be consistent with
a glyosylated derivative of EA. Investigation of the possible formulae consistent with the mass measurement of the fifth UV component (#4) did not yield sufficient
data for proposal of a structure. Of the major MS components, the most abundant (#8) did not yield enough information to support the proposal of a structure,
however the molecular weights and mass defects suggest that they may be dimers of MW,500 species (similar to #6). The second most abundant MS component
(#6) is consistent with a sapogenin. Successive loss of water (m/z 18) is consistent with a poly-hydroxylated compound. The third most abundant MS component (#5,
MW 534) appears to be similar to #6 and has MS/MS losses consistent with a multiply hydroxylated compound like a sapogenin. Losses consisted with neutral loss of a
sugar were not observed.
doi:10.1371/journal.pone.0028737.t001
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prophylactic efficacy in the prevention of biofilm formation using
a static microtiter plate biofilm assay. The only compound
exhibiting meaningful anti-biofilm activity at doses well below
any growth inhibitory effects was EA (Table S1). This finding
supports the hypothesis that EA and EADs present in 220D-F2 are
responsible for the anti-biofilm properties of the extract.
Cytotoxicity of 220D-F2 in normal mammalian cell lines
Normal human (HK-2) and mouse (TKPTS) proximal tubular
kidney cells demonstrated very good tolerance for the extract, and
no IC50 could be identified even at extremely high doses of
7,000 mg/mL (Fig. 10). Rat kidney (NRK-52E) cells and mouse
hepatocytes (AML-12) were slightly more sensitive and had IC50 s
of 4,000 and 7,000 mg/mL, respectively. Human kidney cells were
Figure 4. LC-MS/MS analysis revealed a mixture of ellagic acid and glycosylated ellagic acid derivatives in 220D-F2. Corresponding
ESI(+)-MS and MS/MS data is reported in Table S1. Compound 1. Ellagic Acid xylopyranoside or xylofuanoside Compound 2. Ellagic acid.
Compound 3. Ellagic acid mannopyranoside. The configuration for each of the glycosylated ellagic acids could not be confirmed. Neutral loss of m/z
132 was used to confirm the presence of a pentose attached to ellagic acid.
doi:10.1371/journal.pone.0028737.g004
Figure 5. Anti-biofilm activity of 220D-F2 against genotypically- and phenotypically-diverse strains of S. aureus. A crystal violet
microtiter plate biofilm assay was used to assess the impact of 220D-F2 on biofilm formation. Strain designations are given based on both the
corresponding author’s culture collection (UAMS) and the clonal lineage of each isolate (USA). Statistical significance (*, P,0.05; {, P,0.001) refers to
differences between the untreated cultures and cultures exposed to the indicated concentrations. When available, the isogenic sarA mutant for each
isolate in the absence of 220D-F2 was included as a control; results obtained with all 15 sarA mutants were significantly different from those obtained
with the isogenic parent strain (P,0.001).
doi:10.1371/journal.pone.0028737.g005
R. ulmifolius Extract Inhibits S. aureus Biofilms
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e28737the least impacted and a significant effect in decreasing cell
viability was notable only at concentrations $500 mg/mL. These
results are relevant as the active doses for biofilm inhibition range
from 50–200 mg/mL (depending on the S. aureus strain) and no or
very limited impact (,20%) on cell viability was notable at these
concentrations in the cell lines examined.
Discussion
In a previous study we demonstrated that an ethanolic extract
from the root of R. ulmifolius can be used to limit S. aureus biofilm
formation [28]. However, this work was limited to the crude
extract and examined only one strain of S. aureus. In this report, we
Figure 6. Impact of 220D-F2 on S. aureus growth. Results illustrate growth of UAMS-1 in biofilm medium (BM) supplemented with 200 mg/mL
220D-F2 in 0.2% DMSO (%) or 0.2% DMSO (N) as an excipient control. Growth of the isogenic UAMS-1 sarA mutant (UAMS-929, containing 0.2%
DMSO in comparison with untreated wild type (UAMS-1) and sarA mutant (UAMS-929, m) is shown for comparison.
doi:10.1371/journal.pone.0028737.g006
Table 2. Activity of 220D-F2 (mg/mL) against wild-type strains of Staphylococcus aureus.
Growth Survival Biofilm Formation
USA Type Strain I.D. of wild type
* Strain I.D. of sarA mutant MIC50 MIC90 MBC50 MBC90 MBIC50 MBIC90
100 UAMS-1893 UAMS-1941 380 530 530 740 100 200
200 UAMS-1 UAMS-929 380 530 740 1040 50 50
UAMS-270 - 380 530 1460 2040 100 200
UAMS-601 UAMS-950 530 740 1460 2040 50 100
UAMS-1894 UAMS-1945 380 530 740 1040 50 100
300 UAMS-1625 UAMS-1653 380 530 530 740 50 100
UAMS-1782 UAMS-1804 380 530 380 530 50 100
UAMS-1790 UAMS-1796 380 530 380 530 50 100
400 UAMS-1039 UAMS-1938 530 740 530 740 100 200
500 UAMS-1895 UAMS-1942 740 1040 1040 1460 100 200
600 UAMS-1896 UAMS-1943 530 740 530 1040 100 200
700 UAMS-1897 - 530 740 530 1040 100 200
800 UAMS-1898 UAMS-1944 530 740 1460 2040 100 200
1000 UAMS-1899 UAMS-1930 530 740 1040 1460 100 300
1100 UAMS-1900 UAMS-1931 380 530 740 1460 50 100
*A detailed description of the bacterial strains used in this study has been previously published [52].
doi:10.1371/journal.pone.0028737.t002
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the anti-biofilm properties of the resulting fractions against
genotypically and phenotypically-diverse strains of S. aureus. The
results confirmed that an EA and EAD-rich fraction (220D-F2)
obtained from the roots of R. ulmifolius was effective at preventing
S. aureus biofilm formation irrespective of strain identity. While
addition of the same fraction had no impact on dispersal of an
established biofilm, this limitation was therapeutically relevant in
that inclusion of 220D-F2 was associated with enhanced
susceptibility to functionally-diverse antibiotics including dapto-
mycin, oxacillin, and clindamycin in the specific context of an
established biofilm. Moreover, when the extract was employed
both prophylactically during the colonization process and
therapeutically in combination with daptomycin, it was possible
to completely clear infected catheters of all viable cells.
A few studies [31,32,36] have addressed the phytochemical
makeup of R. ulmifolius and identified some compounds (Table 3),
but it is unlikely that this list is comprehensive. Indeed, the EADs
isolated in this study have not been previously reported for R.
ulmifolius. Importantly, we demonstrated that EA alone has potent
anti-biofilm properties at concentrations (MBIC50,50 mM) well
below those that impact bacterial growth (MIC90.2000 mM). This
is consistent with the hypothesis that the activity of 220D-F2 is
likely to be related to the high content of EA and glycosylated EAs.
The decline in activity when 220D-F2 is divided into four separate
fractions may be related to the EAD content of the various
fractions and possibly the unequal distribution of the most active
forms. More work involving the isolation of substantive amounts of
individual EADs for further testing and structural elucidation by
NMR (nuclear magnetic resonance) is necessary to determine
which compound(s) are most efficacious in preventing S. aureus
biofilm formation and if they act in a distinctly synergistic fashion
when combined.
EA is a polyphenol found at high concentrations in a number of
edible fruits, such as grapes, strawberries, raspberries, blackberries,
and black currants. Berries of the Rosaceae family, in particular,
contain high levels of EA equivalents [37]. EA is derived from
gallic acid, in which two gallic acid molecules are linked by ester
bonds. EA has been the focus of many studies in recent years,
primarily related to its antioxidant [38,39], anti-proliferative [40],
anti-estrogenic [41] anti-inflammatory [42], anti-bacterial [37,43]
and protein kinase CK-2 inhibiting [44] effects. Reports
concerning the biofilm inhibiting properties of EA against
Escherichia coli [45,46] Streptococcus dysgalactiae [47], Pseudomonas
putida [46], and Burkholderia cepacia [46] have also recently emerged.
EADs, on the other hand, have been found to have anti-
plasmodial [48], anti-babesial [49], antibacterial [50] and
antioxidant [50,51] effects. However, to our knowledge, this is
the first report of the anti-biofilm properties of EA and EADs
against S. aureus. This is in contrast to Du ¨rig et al. [47], who
examined the impact of EA on S. aureus biofilm formation but did
not observe any inhibitory activity. This contrast may be
attributable to differences in the methodologies employed in the
respective studies. Specifically, we employ in vitro assays in which
the substrate, whether microtiter plate or catheter, is first coated
with plasma proteins [34,52]. We do this both because indwelling
medical devices are invariably coated with plasma proteins and
because the results we have obtained with our in vitro assays have
been consistent with those obtained using in vivo assays [35]. This
was not done in the study by Du ¨rig et al. [47]. This is potentially
important in that we have also demonstrated that the results
obtained when examining the contribution of specific S. aureus
factors to biofilm formation differ depending on whether the assay
is done with or without plasma coating [34,52,53]. To determine
whether this may account for this discrepancy, we tested both
220D-F2 and EA in a biofilm assay with and without plasma
coating. Our results confirmed that, when the substrate is coated
with plasma proteins, EA elicits a significant decrease in the
biofilm phenotype that is not apparent in the absence of coating
with plasma proteins (Fig. 11). Thus, it is likely that this difference
is related to EA interactions with proteins. At the same time, the
inhibitory activity of 220D-F2 was apparent under both
conditions, which suggests that 220D-F2 contains components
unrelated to EA that also have anti-biofilm properties or that
Figure 7. Impact of 220D-F2 as assessed by confocal microscopy. Microtiter plate biofilm assays were undertaken with UAMS-1 (top) or
UAMS-1782 (bottom) after the addition of either 220D-F2 at the indicated concentrations or excipient (DMSO) to the growth medium. Confocal
images were obtained after 20 hours of incubation. An orthogonal view is included to illustrate overall biofilm architecture at a magnification of 106.
Isogenic sarA mutants grown in BM with DMSO were included as negative controls.
doi:10.1371/journal.pone.0028737.g007
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present in the commercially-available EA preparation.
The focus in this study was on further characterization of the
crude R. ulmifolius extract and confirmation of its anti-biofilm
properties in diverse strains of S. aureus. Nevertheless, the results
discussed above potentially provide important clues about the
mechanistic basis for this activity. Most notably, the fact that the
inhibitory effects of 220D-F2 were apparent with and without
plasma coating suggests that components within the extract are
likely to impact multiple biofilm-associated processes. This also
appears to be the case with sarA in that the negative impact of
mutating sarA on biofilm formation is apparent, albeit to greatly
varying degrees, irrespective of whether the assay is done with
plasma coating [52,54]. Mutation of sarA results in decreased
production of the polysaccharide intercellular adhesion (PIA),
increased production of extracellular nucleases, and increased
production of extracellular proteases [52,53,54]. The impact of
sarA on the production of PIA appears to play a minor role by
comparison to these other factors [53], and this suggests that the
inhibitory effects we observed with 220D-F2 are not mediated by
changes in PIA production. This is consistent with the observation
that 220D-F2 did not inhibit biofilm formation in S. epidermidis
(data not shown). We have demonstrated that the increased
production of both nucleases and proteases contribute to the
biofilm-deficient phenotype of sarA mutants [52,53,54]. However,
the impact of eliminating nuclease production in a sarA mutant is
apparent only when the assay is done without plasma coating. To
the extent that 220D-F2 inhibited biofilm formation both with and
without plasma coating, it is plausible to suggest that the inhibitory
effects may impact both protein-dependent and protein-indepen-
dent mechanisms of biofilm formation in much the same way as
sarA itself. We included sarA mutants as controls based on previous
work demonstrating that mutation of sarA limits biofilm formation
to a therapeutically-relevant degree [34,35], but based on this we
also examined whether the presence of 220D-F2 had any impact
on expression of sarA, and somewhat surprisingly our results to
date suggest that this is not the case (data not shown). Nevertheless,
the results reported in this study provide strong support for the
hypothesis that 220D-F2 or its associated components may well
have therapeutic utility in the specific context of an S. aureus
biofilm-associated infection.
Materials and Methods
Acquisition of botanical materials
Bulk samples of Rubus ulmifolius Schott. (Rosaceae) roots were
collected from wild populations in August 2009 in the village of
Ginestra, Italy. Procedures from the 2003 WHO Guidelines on
Figure 8. Use of 220D-F2 as adjunct therapy with conventional antibiotics. Biofilms were formed on plasma-coated catheters for 24 hours
by growth of the test strain (UAMS-1) in BM. Catheters were then placed in fresh BM containing 200 mg/mL 220D-F2 with or without the indicated
amounts of antibiotic. In the case of all three antibiotics, the concentrations examined correspond to 16or 106the CLSI-defined breakpoint MIC for
a sensitive strain of S. aureus. Statistical significance (*, P,0.05; {, P,0.001) refers to differences between the cultures treated with antibiotic alone
and cultures exposed to both extract 220D-F2 and antibiotic. A. Clindamycin (16: 0.5 mg/mL; 106:5mg/mL); B. Daptomycin (16:1mg/mL; 106:
10 mg/mL); C. Oxacillin (16: 0.5 mg/mL; 106:5mg/mL).
doi:10.1371/journal.pone.0028737.g008
Figure 9. Prophylactic use of 220D-F2 prior to concomitant antibiotic therapy. Biofilms were formed on plasma-coated catheters for
24 hours by growth of the test strain (UAMS-1) in BM containing 200 mg/mL 220D-F2. Catheters were then placed in fresh BM containing 200 mg/mL
220D-F2 with or without 10 mg/mL of daptomycin, which corresponds to 106the CLSI-defined breakpoint MIC for a sensitive strain of S. aureus.
Statistical significance (*, P,0.05; {, P,0.001) refers to differences between the untreated cultures and cultures exposed to the compounds. Results
observed with the isogenic sarA mutant with and without the same concentration of daptomycin but without 220D-F2 are shown for comparison.
doi:10.1371/journal.pone.0028737.g009
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[55] were followed for the collection and identification of bulk and
voucher specimens. Voucher specimens (CQ-164) were deposited
at the Herbarium Lucanum (HLUC) at the Universita ` della Basilicata in
Potenza, Italy. Additional vouchers are in the possession of the first
author. The specimens were identified using the standard Italian
Flora [56] and identification was confirmed at HLUC. All soil and
other contaminants (i.e. insects, other plant species etc.) were
removed from each sample. Roots were cut into small pieces and
air dried. Upon drying, materials were packed into plastic bags
with silica packets and vacuum sealed, and then exported to the
USA under USDA Permit PDEP-09-00228 for phytochemical
evaluation and bioassays.
Extraction and bioassay guided fractionation of plant
materials
Air-dried roots (1 kg) were ground into a fine powder and
extracted with 95% EtOH (2610 L) at room temperature for
72 hours with constant agitation. Filtered extracts were combined,
concentrated at reduced pressure and a temperature ,45uC, and
lyophilized before being re-suspended in water and partitioned in
succession with hexane, ethyl-acetate and butanol (all solvents
acquired from Fisher Chemical, Certified ACS). The partitions
were dried over anhydrous sodium sulfate, concentrated at
reduced pressure, and lyophilized before testing for activity. The
most active partition (butanol) was subjected to column chroma-
tography using Silica gel (0.015–0.040 mm particle size, EMD
Chemicals) and fractions were collected after eluting successively
with mixtures of MeOH:CH2Cl2 (30:70, 40:60, 50:50, 60:40,
70:30, 80:20, 90:10) followed by 100% MeOH and 100% H2O
(18V). Fractions were dried, weighed and tested for anti-biofilm
activity using an established microtiter plate assay (see below).
A preparative HPLC method was developed to split 220D-F2
into 4 additional fractions in an effort to identify the active
constituent(s). Briefly, 220D-F2 was dissolved in 2-propanol:
water (2:8) at a concentration of 50 mg/mL. A C-18 co-
lumn (mBondapak
TM,1 9m m 6300 mm, 125
9
A ˚,1 0mm) was used
to separate 1 mL injections (total 5 mg) with a Waters 600E
system controller and pump and an isocratic mobile phase of
H2O:acetonitrile:2-propanol:formic acid (74:17:8:1) at a flow rate
of 7 mL/min (all solvents HPLC-grade, Fisher Chemical) and
detection at a wavelength of 360 nm using a Waters 486 Tunable
Absorbance Detector and Shimadzu C-R5A Chromatopac.
Fractions were collected at 17.5 (220D-F2-f1), 20.5 (-f2), 27 (-f3)
and 45 (-f4) minutes. The largest single peaks were located in
fractions 2 and 3, whereas fractions 1 and 4 contained multiple
minor peaks. Fractions were collected for chemical analysis and
bioassays described below.
Characterization of major extract components
Further characterization of 220D-F2 (suspended in 5%
isopropanol in H2O, 1 mg/mL) was performed using accurate
mass LC/UV/MS/MS to identify the major components. A Mac-
Mod HALO C18 column (3.06100 mm) was used with a mobile
phase (A: 0.1% formic acid in water; B: 0.1% formic acid in
acentonitrile) with a gradient (hold 2% B for 2 min., 2–50% B
over 18 min, 100% B for 5 min.), flow of 0.4 mL/min and PDA
(photodiode array detector) detection range of 200–790 nm. MS
detection was with a Thermo LTQ Orbitrap Discovery, +ESI
mode, and scan range of 140–2000 Da. Searches of multiple
databases (Human Metabolome Database (version 2.5), Chem-
Spider, SciFinder, and Kyoto Encyclopedia of Genes and
Genomes (KEGG) LIGAND Database) were performed using
chemical formula queries. All mass measurements were within
0.5 mmu of the proposed formulae, well within the expected
measurement tolerances of the mass spectrometer.
Individual phytochemicals tested
In addition to testing the chemically complex R. ulmifolius
extracts for anti-biofilm activity, all known constituents of R.
ulmifolius (Table 2) that were commercially available were
purchased for anti-biofilm analysis using the static microtiter plate
method described below. Ferulic acid, kaempferol, ursolic acid,
quercetin dehydrate, caffeic acid, ellagic acid, and oleanolic acid
were purchased from MP BioMedicals (Solon, OH, USA);
quercetin-3-O-glucuronide and tiliroside from Chromadex (Irvine,
CA, USA); and gallic acid from Acros Organics (NJ, USA).
Compounds were tested for growth and biofilm inhibitory activity
at doses ranging from 25–2000 mM.
Quality control
Extracts and drugs were suspended in either DMSO or PBS
(depending on solubility), then sterile filtered (0.2 mm), and stored
in sterile vials prior to use in all bioassays. Sterility controls were
included in all assays (extract+media). Tests for sterility followed
standard quality control methods [57] to ensure that no microbial
growth was detectable prior to bioassay testing. Prior to
performing bioassays, batches of extract 220D-F2 were checked
for the relative ratios of constituents by RP-HPLC, and were
found to be reproducible. All chemicals (including extract) were
stored at 220uC.
Bacterial strains and growth conditions
The Staphylococcus aureus strains used in these experiments are
listed in Table 1. When available, isogenic strains carrying a
Table 3. Phytochemicals previously isolated from Rubus
ulmifolius [31,32,36].
kaempferol-3-O-(60-p-coumaroyl)-b-D-glucopyranoside *quercetin
kaempferol-3-O-a-L-arabinopyranoside rubanthrone A
kaempferol-3-O-(60-feruloyl)-b-D-glucopyranoside rubanthrone B
kaempferol-3-O-b-D-galactoside rubanthrone C
quercetin-3-O-b-D-glucuronide *caffeic acid
quercetin-3-O-b-D-glucoside tormentic acid
quercetin-3-O-a-L-rhamnoside *ursolic acid
*quercetin-3-O-glucuronide euscaphic acid
luteolin-7-O-b-D-glucuronide *oleanolic acid
kaempferol-3-O-glucuronide 2a-hydroxyursolic acid
kaempferol-3-O-b-D-glucuronide *ferulic acid
kaempferol-3-O-b-D-glucoside *tiliroside
tormentic acid-28-glucoside corosine
23-hydroxy tormentic acid *gallic acid
euscaphic acid-28-glucoside nigaichigoside
ursolic acid-28-glucoside 3-caffeoylquinic acid
1,4-dicaffeoylquinic acid 5-caffeoylquinic acid
4-caffeoylquinic acid *kaempferol
*ellagic acid
*Individual compounds tested for anti-biofilm activity. Results are reported in
Table 3.
doi:10.1371/journal.pone.0028737.t003
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included as negative controls based on the observation that
mutation of sarA results in a reduced capacity to form a biofilm
that can be correlated with increased antibiotic susceptibility
[35,53]. For biofilm assays, strains were grown in tryptic soy broth
(TSB) supplemented with 3.0% NaCl (wt/vol) and 0.5% dextrose
(biofilm medium, BM). In experiments that included daptomycin,
BM was supplemented (wt/vol) with 2.5 mM CaCl2. For all
assays, overnight cultures of the test strains were used to inoculate
fresh medium at an initial cell density of 5610
5 colony-forming
units (CFU) per ml (confirmed with plate counts). This cell density
was achieved by taking the optical density of overnight cultures
and diluting to an OD560 nm of 0.05. Studies examining growth
rate were done at 37uC in BM with constant shaking (200 rpm)
and a volume-to-flask ratio of 0.4.
Determination of MIC and MBC
To determine the minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC) for each fraction,
strains were grown at 37uC in cation-adjusted Mueller-Hinton
broth (CAMHB). MIC and MBC were determined following
Clinical and Laboratory Standards Institute (CSLI) broth micro-
dilution guidelines [58,59]. Briefly, test strains were inoculated into
0.1 ml CAMHB containing varying concentrations of extract. For
MIC, optical density (OD600) was assessed immediately after
inoculation and again after 18 hours using a Biotek Synergy II
microplate reader. Corrections for extract color were done as
previously described [28]. The MIC was defined as the lowest
concentration that inhibited growth to a level $90% (for MIC90)
or $50% (for MIC50) by comparison to untreated control cultures.
MBC was assessed by determining the number of colony-forming
Figure 10. Cytotoxicity of 220D-F2 against normal mammalian cell lines. Cytotoxicity was assessed using a lactate dehydrogenase (LDH)
test following 24 hours of exposure to the extract. Results are reported as the percent of cell viability after exposure to the indicated dosage of 220D-
F2 in the culture growth medium. Statistical significance (*, P,0.05; {, P,0.001) refers to differences observed in comparison to the untreated
(excipient) control. A. Normal human kidney proximal tubular (HK-2) cells; B. Normal mouse kidney proximal tubular (TKPTS) cells; C. Normal rat
kidney (NRK-52E) cells; D. Normal mouse hepatocytes (AML12).
doi:10.1371/journal.pone.0028737.g010
Figure 11. Biofilm inhibition in the presence and absence of human plasma proteins. Previous studies have indicated that ellagic acid is
not an effective biofilm inhibitor for S. aureus [47]. Our data suggest otherwise. UAMS-1 (USA200) and UAMS-1782 (USA300) were used to assess the
efficacy of 220D-F2 and EA in experiments that included or omitted the use of plasma coating for the test wells. Treatment with 220D-F2 elicited a
dose-dependent response in limiting biofilm formation under both growth conditions, whereas ellagic acid inhibited biofilm formation only in
plasma coated wells, suggesting that the mechanistic basis of EA’s biofilm-inhibiting effects involves surface protein recognition or attachment.
doi:10.1371/journal.pone.0028737.g011
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lowest concentration at which the initial density of viable cells was
reduced to a level by $90% (for MBC90)o r$50% (for MBC50)b y
comparison to the untreated control cultures.
Assessment of biofilm formation
The primary biofilm assays, used as a guide during fraction-
ation, were undertaken using a human plasma protein-coated
microtiter plate assay as previously described [53]. Wells were
pre-coated for 24 h at 4uC with 20% human plasma diluted in
carbonate buffer (pH 9.6). After inoculation and addition of the
appropriate media (containing drug or excipient alone), the plates
were incubated without shaking at 37uC for 24 h, the wells were
gently washed twice with 200 ml of phosphate-buffered saline to
remove nonadherent cells. Adherent biofilms were fixed with
200 ml of 100% ethanol prior to staining for 2 min with 200 mlo f
0.41% (wt/vol) crystal violet in 12% ethanol (Protocol Crystal
Violet; Biochemical Sciences, Swedesboro, N.J.). The stain was
then aspirated, and the wells were washed several times with
phosphate-buffered saline. A quantitative assessment of biofilm
formation was obtained by adding 100 ml of 100% ethanol and
incubating at room temperature for 10 min. A total of 50 mlo f
the eluate was then transferred to a sterile polystyrene microtiter
plate and the absorbance (OD595 nm) was determined using a
plate reader. The minimum biofilm-inhibiting concentration
(MBIC) was defined as the lowest concentration of extract in
which biofilm formation was limited to a level $90% (for
MBIC90)o r$50% (for MBIC50) by comparison to the untreated
parent control strain. Additional tests with 220D-F2 and EA
were conducted to examine the influence of plasma proteins
on the relative activity of the drugs. In this case, both coated and
uncoated wells were employed in the static microtiter plate
assay.
Assays examining the impact of different extracts on antibiotic
susceptibility were done using an in vitro model of catheter-
associated biofilm formation [34]. Briefly, 1-cm segments of
fluorinated ethylene propylene catheters (14-gauge Introcan Safety
catheter; B. Braun, Bethlehem, PA) were coated with human
plasma proteins (Sigma-Aldrich, St. Louis, MO, USA), placed in
the wells of a 12-well microtiter plate containing BM, and
inoculated with the test strain at an initial optical density
(OD560 nm) of 0.05. After 24 hours, the BM was replaced with
fresh BM containing 220D-F2 (or excipient alone) with or without
antibiotic. Antibiotics tested were daptomycin, clindamycin, and
oxacillin, all of which were examined at concentrations corre-
sponding to 1 and 10 times (16 and 106) the CLSI-defined
breakpoint MIC defined for an antibiotic-resistant strain of S.
aureus. The medium was replaced in its entirety at 24 hour
intervals for 7 days. Following each 24 hour interval, catheters
were removed and processed to assess viability as previously
described [34,35]. More specifically, catheters were dunked into
sterile PBS several times using a sterile forceps in order to remove
all of the loosely adherent cells from both the interior lumen of the
catheter and external surface. In a second set of experiments,
extracts were added to BM during colonization of plasma-coated
catheters. After 24 hours, catheters were either processed for plate
counts as described above or transferred to fresh BM with and
without antibiotics.
Confocal laser scanning microscopy (CLSM) of static
biofilms
Two S. aureus strains (UAMS-1 and the USA300 isolate UAMS-
1782) and their isogenic sarA mutants (UAMS-929 and UAMS-
1804)weregrown in96well microtiter plates(Costar 3603,Corning
Life Sciences) as described above. After 20 hours, the well contents
were aspirated and the wells gently washed three times with 0.85%
(wt/vol) NaCl. The adherent biofilm was then stained with LIVE/
DEAD stain (Invitrogen) at room temperature in the dark for
18 minutes. After removal of the stain, the wells were gently washed
with 0.85% NaCl before collecting CLSM images using a Zeiss
LSM 510 Meta confocal scanning system and inverted microscope.
SYTO 9 fluorescence was detected by excitation at 488 nm and
emission collected with a 500–530 bandpass filter. All z-sections
were collected at 4-mm intervals using a 106 objective lens. A
0.960.9 mm section of biofilm was selected from the center of the
well for each image. Image acquisition and processing was
performed using LSM Image Browser (Carl Zeiss). Identical
acquisition settings were employed for all samples.
Cell culture and cytotoxicity assays
Normal human kidney proximal tubular (HK-2) cells, normal
rat kidney (NRK-52E) cells, and normal mouse hepatocytes
(AML12) were purchased from the American Type Culture
Collection (ATCC). Normal mouse kidney proximal tubular cells
(TKPTS) were developed and gifted by Dr. Elsa Bello-Reuss
[60]. The four cell lines were cultured with different media,
keratinocyte serum free media (K-SFM) supplemented with
bovine pituitary extract (BPE) and human recombinant epider-
mal growth factor (EGF) for HK-2 cells, Dubelcco’s Modified
Eagle’s Medium (DMEM) for NRK-52E cells, and ATCC
complete growth medium (1:1 mix of DMEM and Ham’s F12
medium supplemented with insulin, transferring, dexamethasone,
and fetal bovine serum) for AML12 and TKPTS cells. Cells were
maintained in humidified air with 5% CO2 at 37uC. Cells were
transferred to 96-well cell culture plates (10,000 cells seeded per
well) and incubated for 24 hours prior to aspirating the media,
adding extract 220D-F2 in serum-free media and undertaking
cytotoxicity tests. To examine the cytotoxic effects of 220D-F2 on
normal mammalian liver and kidney cells, a lactate dehydroge-
nase (LDH) assay was employed. LDH is a stable cytosolic
enzyme that is released upon membrane damage in necrotic cells.
LDH activity can serve as a useful measure for determining drug
toxicity to cell lines.
LDH was measured using a commercial cytotoxicity assay kit
(Promega CytoTox 96H Non-Radioactive Cytotoxicity Assay, WI,
USA), in which LDH released in culture supernatants is measured
with a coupled enzymatic assay, resulting in conversion of a
tetrazolium salt into a red formazan product. The cells were
treated with concentrations of extract 220D-F2 ranging from 0.1–
7,000 mg/mL and incubated in humidified air with 5% CO2 at
37uC for 24 hours. Controls for the extract excipient (20% DMSO
in phosphate buffered saline, PBS), positive LDH control, and
positive LDH control with media and extract were also included.
The sample solution (supernatant) was removed, and the LDH
released from the cells into culture medium treated according to
kit instructions, then measured at an OD490 nm. The maximal
release was obtained after treating cells with a lysis solution for
45 minutes, then treating the supernatant according to kit
instructions. All tests were performed in quadruplicate. The
necrotic percentage (% cytotoxicity) was expressed using the
formula: (sample value/maximal release)6100%.
Statistical analysis
Pair-wise testing was performed based on t tests as formatted in
Sigma StatH Statistical Software Version 2 (SPSS, Inc) with P
values,0.05 considered significant.
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